<DOC>
	<DOCNO>NCT02173990</DOCNO>
	<brief_summary>The PULsAR trial international , investigator-initiated , single arm open-label phase II study . The aim study measure clinical activity combination FOLFIRI-aflibercept homogeneous group patient metastatic colorectal cancer , treat FOLFIRI-aflibercept regimen first line treatment .</brief_summary>
	<brief_title>Aflibercept Chemotherapy First Line Treatment Metastatic Colorectal Cancer Assessable With DCE-US ( PULSAR ) .</brief_title>
	<detailed_description>Patients unresectable metastatic colorectal carcinoma ( mCRC ) histologically proven treated combination Irinotecan/bolus-infusion-5-Fluorouracil/Leucovorin ( FOLFIRI regimen ) aflibercept . On day 1 cycle patient receive aflibercept follow irinotecan , 5-Fluorouracil ( FU ) leucovorin ( FOLFIRI regimen ) . This treatment repeat every 2 week RECIST progression unacceptable toxicity , investigator 's decision patient 's refusal treatment death , whichever come first . All patient assess FOLFIRI-aflibercept Dynamic Contrast Enhanced Ultrasound ( DCE-US ) baseline , D7 ( ± 1 day ) , D28 ( ± 2 day ) . The recruitment period 24 month . The average duration study per patient approximately 12 month , i.e . 3 week screen , 10 month combination FOLFIRI plus aflibercept 30 day follow-up adverse event last dose study treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed date informed consent , willing able comply protocol requirement 2 . Histologically proven adenocarcinoma colon and/or rectum 3 . Metastatic disease confirm clinically/radiologically , evaluable dynamic contrast ultrasound 4 . No prior therapy metastatic disease 5 . Duly document inoperable metastatic disease , i.e . suitable complete curative surgical resection 6 . At least one measurable evaluable lesion assess CTscan MRI ( Magnetic Resonance Imaging ) accord RECIST v1.1 7 . Age ≥ 18 year 8 . Eastern Cooperative Oncology Group ( ECOG ) Performance status ( PS ) 02 9 . Adequate hematological status : neutrophil ( ANC ) ≥ 1.5 x109/L ; platelet ≥ 100x109/L ; haemoglobin ≥ 9g/ dL 10 . Adequate renal function : serum creatinine level &lt; 1.5 mg/dl Glomerular Filtration Rate &gt; 50 ml/min cockroft/ Gault formula 11 . Adequate liver function : serum bilirubin ≤ 1.5 x upper normal limit ( ULN ) , alkaline phosphatase , Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) &lt; 5 x ULN 12 . Proteinuria &lt; 2+ ( dipstick urinalysis ) ≤ 1g/24 hour 13 . Female patient must commit use reliable appropriate method contraception least 6 month end Aflibercept 3 month end Irinotecan ( applicable ) . Male patient partner childbearing potential must agree use contraception addition partner use another contraceptive method least 6 month end Aflibercept 3 month end Irinotecan . 1 . Uncontrolled hypercalcemia 2 . Uncontrolled systemic hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg despite medical therapy ) , history hypertensive crisis , hypertensive encephalopathy 3 . Rightleft shunt severe pulmonary arterial hypertension ( pulmonary artery pressure &gt; 90 mmHg ) 4 . Respiratory distress syndrome 5 . Concomitant antitumor therapy ( e.g . chemotherapy , molecular target therapy , immunotherapy ) 6 . Treatment investigational medicinal product within 28 day prior study entry 7 . History presence Central Nervous System ( CNS ) metastasis unless adequately treat ( e.g . non irradiated CNS metastasis , seizures control standard medical therapy ) 8 . Gilbert 's syndrome 9 . Intolerance atropine sulfate loperamide 10 . Known dihydropyrimidine dehydrogenase deficiency 11 . Treatment Cytochrome P450 3A4 ( CYP3A4 ) inducer unless discontinue &gt; 7 day prior registration 12 . Any follow 3 month prior inclusion : grade 34 gastrointestinal bleeding ( unless due resect tumor ) , treatment resistant peptic ulcer disease , erosive esophagitis gastritis , infectious chronic inflammatory bowel disease , diverticulitis 13 . Other concomitant previous malignancy , except : i/ adequately treat insitu carcinoma uterine cervix , ii/ basal squamous cell carcinoma skin , iii/ cancer complete remission &gt; 5 year , 14 . Any serious uncontrolled nonmalignant disease , major surgery traumatic injury within last 28 day 15 . Pregnant breastfeed woman 16 . Patients know allergy excipients study drug ( include hypersensitivity sulphur hexafluoride component SonoVue ) 17 . History myocardial infarction and/or stroke arterial thrombotic event pulmonary embolism unstable angina pectoris within 6 month prior registration 18 . Poorly control cardiac arrhythmia 19 . Typical Angina Pectoris rest within previous 7 day , significant worsen cardiac symptom previous 7 day , recent intervention coronary artery factor suggest clinical instability ( eg recent deterioration ECG change clinical parameter biological ) , acute heart failure , heart failure stage III IV , severe arrhythmias 20 . Bowel obstruction 21 . History severe tumour bleed bleed disorder 22 . Poorly control anticoagulation therapy ( INR &gt; 3.0 coumadin heparin compound ) 23 . Palliative radiation therapy within 4 week prior registration 24 . St John 's Wort medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>colon and/or rectum</keyword>
</DOC>